Rob Dillard

DocwireNews

Research <a href="https://cardiooncology.onlinejacc.org/content/1/1/54">published</a> in JACC CardioOncology suggests that neurohormonal therapies are associated with higher left ventricular ejection fraction (LVEF) during follow-up among cancer patients undergoing chemotherapy.In this meta-analysis, researchers included 17 randomized clinical trials of comprised of 1,984 adult patients that underwent chemotherapy and neurohormonal therapies such as &beta;-blockers, mineralocorticoid receptor antagonists, or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and assessed efficacy compared to a placebo with follow-up of four or more weeks. The primary outcome was change in left ventricular ejection fraction (LVEF) from baseline to the end of the trial. Other outcomes of interest were measures of LV size, strain, and diastolic function. Pooled estimates for each outcome were reported as standardized mean difference and weighted mean difference between the neurohormonal therapy and placebo groups using random effects models.According to the results of the study, in pooled analysis, the researchers observed that neurohormonal therapy was associated with significantly higher LVEF upon follow-up juxtaposed to placebo therapy, but with significant heterogeneity in the pooled estimate (I2&nbsp;=&nbsp;96%).Moreover, compared with placebo-treated patients, neurohormonal therapies experienced a 3.96% (95% CI, 2.90 to 5.02) less decline in LVEF estimated by weighted mean difference, but with significant heterogeneity (I2&nbsp;=&nbsp;98%). The study also revealed a trend toward lower adverse clinical events with neurohormonal therapy versus place that was not statistical significance (risk ratio: 0.80 95% CI, 0.53 to 1.20; I2&nbsp;=&nbsp;71%).&ldquo;In this study-level pooled analysis, we observed a significant, but small, benefit of neurohormonal therapies in reducing decline in LV systolic function among patients undergoing chemotherapy,&rdquo; the researchers wrote in conclusion.<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy <a href="https://t.co/8QEU9YFBJ2">https://t.co/8QEU9YFBJ2</a>
&mdash; James V Talano MD MM FACC (@jvtalano) <a href="https://twitter.com/jvtalano/status/1176834309984047110?ref_src=twsrc%5Etfw">September 25, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&ldquo;However, owing to the substantial heterogeneity across the 15 modest-sized studies and potential for publication bias in this updated meta-analysis, our study findings are not sufficient to recommend routine use of RAAS inhibitors or &beta;-blockers as cardioprotective strategies in patients undergoing cardiotoxic chemotherapy (predominantly with anthracycline-based regimens). There is an enduring need for future, adequately powered randomized clinical trials to test the effects of cardioprotective therapies on both cardiovascular and cancer outcomes.&rdquo;<blockquote class="twitter-tweet" data-width="500" data-dnt="true">
Efficacy of Neurohormonal Therapies in Preventing Cardiotoxicity in Patients With Cancer Undergoing Chemotherapy. Study sought to assess the effects of neurohormonal therapies in preventing cardiotoxicity in patients receiving chemotherapy <a href="https://twitter.com/JACCJournals?ref_src=twsrc%5Etfw">@JACCJournals</a> <a href="https://t.co/04B6UQvZvx">https://t.co/04B6UQvZvx</a> <a href="https://t.co/CgLYvgOUOO">pic.twitter.com/CgLYvgOUOO</a>
&mdash; Elsevier Cardiology (@ELS_Cardiology) <a href="https://twitter.com/ELS_Cardiology/status/1181917291291828227?ref_src=twsrc%5Etfw">October 9, 2019</a>
</blockquote><script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script>&nbsp;

MarkAlain Déry, DO

The Significant Danger Measles Pose for Unvaccinated Children

Infectious Disease

Andrew Moreno

Antithrombotic Care in Hemophilia: A Summary of Multi-Organizational Clinical Practice Guidance

Hemophilia

James Tumlin, MD

Joel M. Topf, MD, FACP

Proteinuria Remission With Sparsentan in FSGS

NKF Spring Clinical Meetings 2025

Latest News

Neurohormonal Therapies May Prevent Cardiotoxicity in Cancer Patients Undergoing Chemotherapy

Cardiology

Research published in JACC CardioOncology suggests that neurohormonal therapies are associated with higher left ventricular ejection fraction (LVEF) during follow-up among ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HER2 Breast Cancer

HR Breast Cancer

Triple-Negative Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe